Skip to main content
Premium Trial:

Request an Annual Quote

Horizon to Use Genome Editing Technology to Support Bayer Pharma Cancer R&D Programs

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has signed an agreement with Bayer Pharma for the use of Horizon's Genesis genome editing technology in support of Bayer's cancer R&D programs.

Horizon will use its platform to develop human isogenic cell lines for use in Bayer's programs in order to deliver cell lines that more accurately model the disease-relevant mutations found in human tumors.

Genesis allows for the alteration of endogenous gene sequence of human and mammalian cell lines without unwanted or confounding genotypes and/or phenotypes and can more accurately reflect patient genotypes in human cancer cell lines derived from human tumors, Horizon said.

Financial and other terms of the deal were not disclosed.